Joanne Xiu, Vice President, Clinical and Translational Research at Caris Life Sciences, shared on LinkedIn:
“In the new era of targeted therapy for breast cancer, ESR1 mutations play a pivotal role as actionable biomarkers; but not all ESR1 mutations are created equal!
Excited to share our latest study published in Clinical Cancer Research, leveraging molecular profiling and real-world data from nearly 39,000 breast tumors to demonstrate that ESR1 mutation subtype, mutational complexity, and ER pathway activity may influence treatment benefit from elacestrant.
As next-generation endocrine therapies continue to expand, these findings highlight the importance of moving beyond binary biomarker testing toward more precise, variant-specific treatment strategies to advance personalized cancer care.”
Title: Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer
Authors: George W. Sledge, Joanne Xiu, Suzanne Fuqua, Jennifer R. Ribeiro, Heather McArthur, Matthew J. Oberley, Milan Radovich, David Spetzler, Virginia Kaklamani.
Read the full article.
This also can be interesting:
